The FDA has accepted Repros Therapeutics, Inc.'s application for approval of Androxal.
News & Analysis: Repros Therapeutics
Repros Therapeutics' stock is among today's top gainers after the company's lead experimental drug goes head-to-head against a rival and easily comes out on top.
Clinical data sends one stock up 137% on the week while a global pharmaceutical company announces three major collaborations ... in one day!
Pernix, Myriad, Repros and OraSure were four big winners in the biotech space during the past two days. Here's the back story on these pharmaceutical stock pops.
Repros shares soar after a favorable meeting with the Food and Drug Administration. Should shareholders applaud this latest news?
Repros wins meeting with FDA for oral testosterone frontrunner Androxal after FDA concerns last month tanked shares
Johnson & Johnson, Orexigen, Repros, and Auxilium could all make health care headlines today. Let’s see why.
NxStage Medical, Immunogen, and Repros Therapeutics make this week's most horrendous health-care performers.
A surprise FDA approval, positive early-stage pancreatic cancer trial results, and a unanimous FDA panel recommendation for what could be a $7 billion drug are among this week's top biotech stories.
Which health-care stocks struck out the worst this week? Healthways, Repros Therapeutics, and Ziopharm -- along with Pacific Biosciences -- swung and missed badly.